AstraZeneca stock gains as Deutsche Bank and Berenberg adjust targets after trial news
Published on 09/15/2026 at 14:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AstraZeneca Plc stock (ISIN US6549022043) is trading higher in the United States while fresh analyst moves on September 15, 2026 highlight a more cautious but still constructive view on the pharma group’s valuation. According to Investing.com on September 15, 2026, Deutsche Bank has upgraded AstraZeneca shares to Hold and lifted its price target to GBP117.00 from GBP115.00, while Berenberg maintains a Buy recommendation but cuts its target to 150 GBP per Goldesel.
Fresh analyst calls reshape AstraZeneca stock narrative
As of September 15, 2026, Deutsche Bank’s shift from Sell to Hold marks a notable change in sentiment toward AstraZeneca stock after recent clinical trial developments. According to Investing.com on September 15, 2026, the bank raised its price target to GBP117.00 from GBP115.00 and now sees the risk-reward profile of AstraZeneca shares as more balanced at current levels.
Berenberg, meanwhile, remains fundamentally positive on AstraZeneca stock but has scaled back its upside expectations. As Goldesel reported on September 15, 2026, Berenberg cut its target from 160 GBP to 150 GBP, a reduction of 10 GBP or 6.25 percent, while keeping a Buy rating. This adjustment reflects a more cautious stance on near-term upside but still points to meaningful potential compared with the latest London price around 121.10 GBP cited by finanzen.ch on September 15, 2026.
Oncology pipeline wins and setbacks set the tone
The latest analyst actions come against a backdrop of mixed news from AstraZeneca’s oncology pipeline, which remains central to the investment case. As Clinical Trials Arena reported on September 14, 2026, two lung cancer therapies, Enhertu and Tagrisso, recently achieved Phase III success in the DESTINY-Lung04 and ADAURA trials, while the breast cancer therapy Etcamah (camizestrant) failed to meet its primary endpoint in the Phase III SERENA-4 study.
The failure of Etcamah to show a progression-free survival benefit in hormone receptor-positive, HER2-negative metastatic breast cancer patients was highlighted again by Morningstar on September 15, 2026. Morningstar noted that it lowered its 2035 revenue estimate for Etcamah by USD 700 million to USD 1.8 billion but still maintains a fair value estimate for AstraZeneca of GBX 13,500, corresponding to about USD 184 per share, and sees shares as modestly undervalued.
For investors in AstraZeneca stock, this combination of two high-profile trial wins and one notable setback underscores both the breadth of the pipeline and the inherent risk in late-stage drug development. The fact that Morningstar’s fair value estimate remains unchanged despite the reduced Etcamah expectations suggests that other oncology assets, including Tagrisso and Enhertu, continue to drive the long-term earnings and cash flow story, even as they now must offset the lower projected contribution from Etcamah.
Recent trading performance and market figures
On the U.S. market, AstraZeneca stock trades on the New York Stock Exchange under the AZN ticker. According to premarket price activity cited by Yahoo Finance on September 14, 2026, AstraZeneca shares were up 1.86 percent at USD 163.14, reflecting investor interest following the latest pipeline updates and analyst commentary. This U.S. level can be compared with the London quote of around 121.10 GBP on September 15, 2026 reported by finanzen.ch, underlining a slight intraday decline of about 0.4 percent in the home market.
MarketBeat data give an additional snapshot of how AstraZeneca stock is currently valued relative to analyst expectations. According to MarketBeat on September 15, 2026, AstraZeneca shares recently opened at USD 163.75 in New York trading and the stock carries a consensus rating of Moderate Buy with an average target price of USD 206.67. Relative to the USD 163.75 opening level, this implies roughly 26.2 percent upside to the average target, which gives retail investors a clear quantified gauge of how much potential analysts still see despite recent volatility.
The same MarketBeat overview notes that institutional investors and hedge funds own about 20.35 percent of AstraZeneca’s stock, underlining the strong presence of professional investors alongside retail shareholders. For individual investors, high institutional ownership can be a sign that the stock is widely followed and that new information, such as trial outcomes or guidance changes, tends to be rapidly reflected in the price.
Consensus targets and risk factors
Beyond Deutsche Bank and Berenberg, other analyst houses have updated or initiated coverage, feeding into the current consensus picture. According to Investing.com, RBC Capital recently initiated coverage of AstraZeneca stock with an Outperform rating and set a price target of GBP145.00. Compared with the London price around 121.10 GBP on September 15, 2026, RBC’s target implies approximately 19.8 percent upside, while Berenberg’s 150 GBP target points to a more ambitious potential rise of about 23.8 percent from the same reference level.
Morningstar’s fair value estimate provides an additional valuation anchor that is grounded in long-term cash flow projections. As Morningstar outlined on September 15, 2026, its fair value estimate of GBX 13,500 per share remains in place and corresponds to about USD 184 per share for AstraZeneca. With AstraZeneca’s New York level around USD 163–164 in mid-September 2026, the fair value still sits roughly 12.2 percent above the recent trading range, supporting the view that the stock is modestly undervalued despite recent clinical setbacks.
However, the key risk highlighted by recent reports is the binary nature of late-stage trials, especially in oncology, where failures like Etcamah’s can quickly remove hundreds of millions of dollars from future revenue projections. Morningstar reduced its 2035 Etcamah revenue estimate by about USD 700 million to USD 1.8 billion, and while that cut did not shift its overall valuation, it serves as a reminder that AstraZeneca’s growth story depends on sustained success across a broad portfolio of experimental drugs, not just one or two flagship assets.
Events and reporting dates for AstraZeneca stock watchers
In addition to trial news and analyst actions, investors in AstraZeneca stock are monitoring upcoming corporate events such as earnings releases and R&D updates. While the latest search results focus on analyst ratings and clinical trial outcomes, AstraZeneca’s investor-relations calendar on its corporate site provides detailed scheduling of future financial reports and capital markets updates. According to AstraZeneca, investors can find the next earnings date and major investor events in the financial calendar section, which is regularly updated around upcoming quarters and strategic presentations.
For long-term shareholders, these dates are key checkpoints for confirming whether the company’s revenue, margin and guidance trends align with the expectations embedded in current analyst targets such as the USD 206.67 consensus cited by MarketBeat. A quarter in which several major oncology programs deliver positive data could support the case for multiple expansion, while a cluster of negative readouts like the Etcamah setback might push analysts to trim targets further, as Berenberg has already done.
AstraZeneca stock level as of mid-September 2026
As of the latest available snapshot in mid-September 2026, AstraZeneca stock opened around USD 163.75 on the New York Stock Exchange, with premarket indications near USD 163.14 on September 14, 2026 and London trading around 121.10 GBP on September 15, 2026. These levels position the shares below Morningstar’s implied fair value of about USD 184 and under the average analyst target of USD 206.67 mentioned by MarketBeat. For investors, the gap between the current quote and these valuation markers captures both the perceived upside and the uncertainties tied to future trial results and earnings trajectories.
AstraZeneca stock key data
- Company: AstraZeneca Plc
- ISIN: US6549022043
- Ticker: AZN
- Trading venue: New York Stock Exchange
- Price (as of September 15, 2026): 163.75 USD
- Market capitalization: (as of September 15, 2026)
- Sector / Industry: Pharmaceuticals / Biotechnology
- Index membership: FTSE 100
